Literature DB >> 17913812

Prion strain- and species-dependent effects of antiprion molecules in primary neuronal cultures.

Sabrina Cronier1, Vincent Beringue, Anne Bellon, Jean-Michel Peyrin, Hubert Laude.   

Abstract

Transmissible spongiform encephalopathies (TSE) arise as a consequence of infection of the central nervous system by prions and are incurable. To date, most antiprion compounds identified by in vitro screening failed to exhibit therapeutic activity in animals, thus calling for new assays that could more accurately predict their in vivo potency. Primary nerve cell cultures are routinely used to assess neurotoxicity of chemical compounds. Here, we report that prion strains from different species can propagate in primary neuronal cultures derived from transgenic mouse lines overexpressing ovine, murine, hamster, or human prion protein. Using this newly developed cell system, the activity of three generic compounds known to cure prion-infected cell lines was evaluated. We show that the antiprion activity observed in neuronal cultures is species or strain dependent and recapitulates to some extent the activity reported in vivo in rodent models. Therefore, infected primary neuronal cultures may be a relevant system in which to investigate the efficacy and mode of action of antiprion drugs, including toward human transmissible spongiform encephalopathy agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913812      PMCID: PMC2168876          DOI: 10.1128/JVI.01502-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

Review 1.  Approaches to therapy of prion diseases.

Authors:  Charles Weissmann; Adriano Aguzzi
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

2.  Eight prion strains have PrP(Sc) molecules with different conformations.

Authors:  J Safar; H Wille; V Itri; D Groth; H Serban; M Torchia; F E Cohen; S B Prusiner
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

3.  Development of polarity in cerebellar granule neurons.

Authors:  S K Powell; R J Rivas; E Rodriguez-Boulan; M E Hatten
Journal:  J Neurobiol       Date:  1997-02

4.  A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie.

Authors:  Véronique Gayrard; Nicole Picard-Hagen; Catherine Viguié; Valerie Laroute; Olivier Andréoletti; Pierre-Louis Toutain
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

5.  Effectiveness of polyene antibiotics in treatment of transmissible spongiform encephalopathy in transgenic mice expressing Syrian hamster PrP only in neurons.

Authors:  R Demaimay; R Race; B Chesebro
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Selective neuronal targeting in prion disease.

Authors:  S J DeArmond; H Sánchez; F Yehiely; Y Qiu; A Ninchak-Casey; V Daggett; A P Camerino; J Cayetano; M Rogers; D Groth; M Torchia; P Tremblay; M R Scott; F E Cohen; S B Prusiner
Journal:  Neuron       Date:  1997-12       Impact factor: 17.173

7.  Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.

Authors:  S Haïk; J P Brandel; D Salomon; V Sazdovitch; N Delasnerie-Lauprêtre; J L Laplanche; B A Faucheux; C Soubrié; E Boher; C Belorgey; J J Hauw; A Alpérovitch
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

Review 8.  Prions.

Authors:  S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

Review 9.  Prion propagation in cultured cells.

Authors:  Jérôme Solassol; Carole Crozet; Sylvain Lehmann
Journal:  Br Med Bull       Date:  2003       Impact factor: 4.291

10.  Proteinase-resistant protein in human neuroblastoma cells infected with brain material from Creutzfeldt-Jakob patient.

Authors:  A Ladogana; Q Liu; Y G Xi; M Pocchiari
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

View more
  29 in total

1.  PDK1 decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases.

Authors:  Mathéa Pietri; Caroline Dakowski; Samia Hannaoui; Aurélie Alleaume-Butaux; Julia Hernandez-Rapp; Audrey Ragagnin; Sophie Mouillet-Richard; Stéphane Haik; Yannick Bailly; Jean-Michel Peyrin; Jean-Marie Launay; Odile Kellermann; Benoit Schneider
Journal:  Nat Med       Date:  2013-08-18       Impact factor: 53.440

2.  A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.

Authors:  N C Ferreira; L M Ascari; A G Hughson; G R Cavalheiro; C F Góes; P N Fernandes; J R Hollister; R A da Conceição; D S Silva; A M T Souza; M L C Barbosa; F A Lara; R A P Martins; B Caughey; Y Cordeiro
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Comparison of abnormal isoform of prion protein in prion-infected cell lines and primary-cultured neurons by PrPSc-specific immunostaining.

Authors:  Misaki Tanaka; Ai Fujiwara; Akio Suzuki; Takeshi Yamasaki; Rie Hasebe; Kentaro Masujin; Motohiro Horiuchi
Journal:  J Gen Virol       Date:  2016-06-06       Impact factor: 3.891

4.  Endogenous proteolytic cleavage of disease-associated prion protein to produce C2 fragments is strongly cell- and tissue-dependent.

Authors:  Michel Dron; Mohammed Moudjou; Jérôme Chapuis; Muhammad Khalid Farooq Salamat; Julie Bernard; Sabrina Cronier; Christelle Langevin; Hubert Laude
Journal:  J Biol Chem       Date:  2010-02-12       Impact factor: 5.157

5.  Prion propagation and toxicity occur in vitro with two-phase kinetics specific to strain and neuronal type.

Authors:  Samia Hannaoui; Layal Maatouk; Nicolas Privat; Etienne Levavasseur; Baptiste A Faucheux; Stéphane Haïk
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

6.  Engineering a murine cell line for the stable propagation of hamster prions.

Authors:  Matthew E C Bourkas; Hamza Arshad; Zaid A M Al-Azzawi; Ondrej Halgas; Ronald A Shikiya; Mohadeseh Mehrabian; Gerold Schmitt-Ulms; Jason C Bartz; Joel C Watts
Journal:  J Biol Chem       Date:  2019-01-31       Impact factor: 5.157

7.  The physical relationship between infectivity and prion protein aggregates is strain-dependent.

Authors:  Philippe Tixador; Laëtitia Herzog; Fabienne Reine; Emilie Jaumain; Jérôme Chapuis; Annick Le Dur; Hubert Laude; Vincent Béringue
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

Review 8.  Cellular and molecular actions of Methylene Blue in the nervous system.

Authors:  Murat Oz; Dietrich E Lorke; Mohammed Hasan; George A Petroianu
Journal:  Med Res Rev       Date:  2011-01       Impact factor: 12.944

9.  Prion-induced activation of cholesterogenic gene expression by Srebp2 in neuronal cells.

Authors:  Christian Bach; Sabine Gilch; Romina Rost; Alex D Greenwood; Marion Horsch; Glaucia N M Hajj; Susanne Brodesser; Axel Facius; Sandra Schädler; Konrad Sandhoff; Johannes Beckers; Christine Leib-Mösch; Hermann M Schätzl; Ina Vorberg
Journal:  J Biol Chem       Date:  2009-09-11       Impact factor: 5.157

Review 10.  The role of prion strain diversity in the development of successful therapeutic treatments.

Authors:  Sara A M Holec; Alyssa J Block; Jason C Bartz
Journal:  Prog Mol Biol Transl Sci       Date:  2020-08-28       Impact factor: 3.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.